Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide or Everolimus with Endocrine Therapy in PIK3CA Wild-type/Mutant Advanced Breast Cancer
NCT05983107Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, everolimus in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2023; status: recruiting.
02
Drugs
tucidinostateverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05983107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983107.